Tarsus Pharmaceuticals (TARS) Assets (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Assets of $581.1 million for Q1 2026, up 16.05% year-over-year from $500.8 million in Q1 2025, and up 3.38% quarter-over-quarter from $562.2 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Assets (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Assets history runs 8 years deep, the most recent figure standing at $581.1 million for Q1 2026.
- In Q1 2026, Assets rose 16.05% year-over-year to $581.1 million; the TTM figure through Mar 2026 stood at $581.1 million (up 16.05% YoY), while the FY2025 annual figure was $562.2 million, up 49.12% from the prior year.
- Assets for Q1 2026 stood at $581.1 million, up from $562.2 million in the prior quarter.
- The five-year high for Assets was $581.1 million in Q1 2026, with the low at $181.5 million in Q1 2022.
- The 5-year median for Assets is $349.3 million (2024), against an average of $352.1 million.
- The sharpest annual moves came in 2023 and 2024: Assets decreased 25.27% in 2023, then surged 99.47% in 2024.
- Tarsus Pharmaceuticals' Assets stood at $227.9 million in 2022, then climbed by 16.51% to $265.5 million in 2023, then jumped by 42.0% to $377.0 million in 2024, then soared by 49.12% to $562.2 million in 2025, then advanced by 3.38% to $581.1 million in 2026.
- Business Quant data shows TARS's Assets at $581.1 million in Q1 2026, $562.2 million in Q4 2025, and $534.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 611.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 611.14 Mn |
| Mar 31, 2026 | 581.14 Mn |
| Dec 31, 2025 | 562.16 Mn |
| Sep 30, 2025 | 534.56 Mn |
| Jun 30, 2025 | 494.99 Mn |
| Mar 31, 2025 | 500.75 Mn |
| Dec 31, 2024 | 376.99 Mn |
| Sep 30, 2024 | 376.30 Mn |
| Jun 30, 2024 | 376.84 Mn |
| Mar 31, 2024 | 349.28 Mn |
| Dec 31, 2023 | 265.49 Mn |
| Sep 30, 2023 | 268.33 Mn |
| Jun 30, 2023 | 188.93 Mn |
| Mar 31, 2023 | 211.21 Mn |
| Dec 31, 2022 | 227.86 Mn |
| Sep 30, 2022 | 236.47 Mn |
| Jun 30, 2022 | 252.83 Mn |
| Mar 31, 2022 | 181.48 Mn |
| Dec 31, 2021 | 178.91 Mn |
| Sep 30, 2021 | 190.41 Mn |